Results 241 to 250 of about 213,141 (301)
Post‐Translational Regulation of CD8+ T Cell Fate and Dysfunction in Tumor Immunity
Advanced Science, EarlyView.This review delineates how post‐translational modifications (PTMs) function as a central regulatory interface governing CD8+ T cell activation, differentiation, persistence, and exhaustion in antitumor immunity. By integrating antigenic, metabolic, and microenvironmental cues, diverse PTM programs coordinate transcriptional and chromatin states that ...
Zihao Zhou +8 more
wiley +1 more source
Trained Memory of Uterine Macrophages Improves Subsequent Pregnancy Outcomes
Advanced Science, EarlyView.This study identifies that pregnancy imprints a durable, pregnancy‐specific form of trained immune memory in uterine macrophages, marked by the emergence of LILRB3+/PIR‐B+ cells that expand across gestations, acquire a tolerogenic and metabolically rewired phenotype, and actively protect against inflammatory pregnancy loss in mice.
Jing Wang +8 more
wiley +1 more source
Investigating Phase Separation in Genome Folding via Multiscale Computational Modeling
Advanced Science, EarlyView.Phase separation is emerging as a multiscale organizing principle of genome folding across scales, from nucleosomes and transcriptional condensates to chromatin domains and nuclear compartments. By integrating physics‐based simulations with data‐driven inference, computational modeling now links molecular interactions to nuclear architecture and points
Jiahu Tang +3 more
wiley +1 more source
Effects of antineoplastic phospholipids on parameters of cell differentiation in U937 cells [PDF]
, 1990 Berkovic, D. +4 more
core
Advanced Intelligent Systems, EarlyView.Droplet‐based microfluidics enables precise, high‐throughput microscale reactions but continues to face challenges in scalability, reproducibility, and data complexity. This review examines how artificial intelligence enhances droplet generation, detection, sorting, and adaptive control and discusses emerging opportunities for clinical and industrial ...
Junyan Lai +10 more
wiley +1 more source
American Journal of Hematology, EarlyView.ABSTRACT The addition of midostaurin (MIDO) to intensive chemotherapy (IC) improves survival in younger adults with FLT3‐mutated acute myeloid leukemia (AML); however, real‐world data in elderly patients (≥ 60 years) are limited. This large, retrospective, multicenter study from three European registries (PETHEMA, FILO, DATAML) evaluated MIDO+IC (n ...
Gaspar Aspas Requena +31 more
wiley +1 more source
Selinexor and Venetoclax Combination in Patients With Relapsed or Refractory Acute Myeloid Leukemia
American Journal of Hematology, EarlyView.ABSTRACT Preclinical studies showed a synergistic antileukemia activity with combination of selective XPO1 inhibitor selinexor (SEL) and venetoclax (VEN), with potential to overcome VEN resistance by reducing the anti‐apoptotic protein MCL1. In an investigator‐sponsored, open‐label, phase Ib study (NCT03955783), adult patients with relapsed or ...
Somedeb Ball +11 more
wiley +1 more source
American Journal of Hematology, EarlyView.ABSTRACT Mantle cell lymphoma (MCL) is a B‐cell malignancy with a chronically relapsing clinical course and pronounced genetic heterogeneity. To investigate the clonal dynamics underlying early disease relapse, we performed single‐cell RNA sequencing of paired tumor samples collected at diagnosis and at first relapse. Inference of copy number variants (
Dmitry Manakov +14 more
wiley +1 more source
Epidemiology of Cancer‐Associated Venous Thromboembolism Across the United States
American Journal of Hematology, EarlyView.ABSTRACT Prior epidemiological studies on cancer‐associated venous thromboembolism (VTE) were limited by homogenous patient populations. We leverage Cosmos, a collaborative dataset of Epic electronic health record systems, to conduct an updated evaluation of cancer‐associated VTE in the United States (US).
Barbara D. Lam +7 more
wiley +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Targeting leukemia inhibitory factor in pancreatic adenocarcinoma
Expert Opinion on Investigational Drugs, 2023The Leukemia Inhibitory Factor (LIF) is a member of the interleukin-6 (IL-6) cytokine family. Known to induce differentiation of myeloid leukemia cells, evidence has accumulated supporting its role in cancer evolution through regulating cell differentiation, renewal, and survival.
Jing Wang +5 more
openaire +2 more sources